We identified potentially useful targeted drugs for RUNX1mut BP-CML patients, including mTOR inhibitors, glucocorticoids, VEGFR inhibitors, and BCL2 inhibitors. This evidence concerns the gene KDR and chronic myelogenous leukemia, BCR-ABL1 positive.